Halucenex Achieves 80% Remission in PTSD Patients with Psilocybin

In a Phase II clinical trial, Halucenex Life Sciences Inc (ASX: ME1)., a wholly-owned subsidiary, has achieved promising results in treating treatment-resistant Post Traumatic Stress Disorder (PTSD) with psilocybin. Out of the first five patients who received two doses of Halucenex's synthetic psilocybin aqueous solution, Lucenex, 80% experienced complete remission from their PTSD symptoms.

Additionally, these patients reported a remarkable 57% reduction in depression scores and a 50% reduction in anxiety scores from baseline to day 44 of treatment. These results are significant, considering traditional treatments for anxiety and depression are only effective in about 20-30% of cases. The findings could open the door to substantial commercial opportunities for the company. This study is ongoing, with an additional 13 patients expected to provide further validation of Halucenex's potential in the coming months.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com